The Incidence and Clinical Significance of Paraneoplastic Syndromes in Patients with Hepatocellular Carcinoma.
- Author:
Uh Young HUH
1
;
Jin Hyuk KIM
;
Byung Ho KIM
;
Ki Deuk NAM
;
Jae Young JANG
;
Nam Hoon KIM
;
Sang Kil LEE
;
Kwang Ro JOO
;
Seok Ho DONG
;
Hyo Jong KIM
;
Young Woon CHANG
;
Joung Il LEE
;
Rin CHANG
Author Information
1. Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea. kimbh@khu.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Hepatocellular carcinoma;
Paraneoplastic syndrome;
Incidence;
Survival
- MeSH:
Aged;
Carcinoma, Hepatocellular/*complications/mortality;
English Abstract;
Female;
Humans;
Liver Neoplasms/*complications/mortality;
Male;
Middle Aged;
Paraneoplastic Syndromes/complications/diagnosis
- From:The Korean Journal of Hepatology
2005;11(3):275-283
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Patients with hepatocellular carcinoma (HCC) may manifest paraneoplastic syndromes such as hypercholesterolemia, hypoglycemia, hypercalcemia and erythrocytosis. This study was aimed at evaluating the incidence and clinical significance of paraneoplastic syndromes in Korean HCC patients. METHODS: The medical records of 165 HCC patients who were diagnosed and died in the Kyung Hee University Hospital, were reviewed retrospectively. The following variables were analyzed: age, gender, hepatitis markers, platelet, liver function test, alpha-fetoprotein (AFP), Child-Pugh score, tumor features, and the duration of their survival. RESULTS: In total, paraneoplastic syndromes were presented in 43.6% of the HCC patients during the course of their disease. Hypercholesterolemia was solely presented in 14.5%, hypoglycemia in 12.7% and hypercalcemia in 7.8%. The patients who presented with more than 2 syndromes were 8.5%. While 80% of erythrocytosis (4/5) and 51.6% of hypercholesterolemia (16/31) was presented at the time of HCC diagnosis, hypoglycemia and hypercalcemia mainly occurred as terminal events. The patients with paraneoplastic syndromes were younger and had higher rates of portal vein thrombosis, bi-lobar tumor involvement and tumor more of more than 10 cm in diameter, compared to those patients without them. The proportion of patients with a serum AFP more than 400 ng/mL tended to be higher in the patients with paraneoplastic syndromes. The HCC patients with paraneoplastic syndromes, except for erythrocytosis, had a shorter survival than those patients without them. CONCLUSIONS: Paraneoplastic syndromes are not infrequently presented in HCC patients, especially at an advanced stage, and the survival of these patients is relatively shorter.
